[redacted]3

10/061,128

FILE 'HOME' ENTERED AT 15:42:34 ON 07 MAR 2003

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLAPS — SINCE FILE ENTRY: 0.21 — TOTAL SESSION: 0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 15:42:52 ON 07 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 15:42:52 ON 07 MAR 2003

FILE 'CAPLUS' ENTERED AT 15:42:52 ON 07 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:42:52 ON 07 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 15:42:52 ON 07 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s hepatitis B and 2 (w) fluoro beta D nucleoside
L1 2 HEPATITIS B AND 2 (W) FLUORO BETA D NUCLEOSIDE

=> d l1 bib abs 1-2

L1 ANSWER 1 OF 2 USPATFULL
AN 2002:344441 USPATFULL
TI 2'-fluoronucleosides
IN Schinazi, Raymond F., Decatur, GA, UNITED STATES
Liotta, Dennis C., McDonough, GA, UNITED STATES
Chu, Chung K., Athens, GA, UNITED STATES
McAtee, J. Jeffrey, Mobile, AL, UNITED STATES
Shi, Junxing, Decatur, GA, UNITED STATES
Choi, Yongseok, Athens, GA, UNITED STATES
Lee, Kyeong, Athens, GA, UNITED STATES
Hong, Joon H., Athens, GA, UNITED STATES
PI US 2002198171 A1 20021226
AI US 2002-61128 A1 20020130 (10)
RLI Continuation of Ser. No. US 1999-257130, filed on 25 Feb 1999, GRANTED, Pat. No. US 6348587
PRAI US 1998-75893P 19980225 (60)
US 1998-80569P 19980403 (60)
DT Utility
FS APPLICATION
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3626
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A class of 2'-fluoro-nucleoside compounds are disclosed which are useful in the treatment of **hepatitis B** infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: ##STR1##

wherein

Base is a purine or pyrimidine base;

R.sup.1 is OH, H, OR.sup.3, N.sub.3, CN, halogen, including F, or CF.sub.3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base;

R.sup.2 is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R.sup.2 is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and

R.sup.3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 2 USPATFULL
AN 2002:34547 USPATFULL
TI 2'-Fluoronucleosides
IN Schinazi, Raymond F., Decatur, GA, United States
Liotta, Dennis C., McDonough, GA, United States
Chu, Chung K., Athens, GA, United States
McAtee, J. Jeffrey, Atlanta, GA, United States
Shi, Junxing, Decatur, GA, United States
Choi, Yongseok, Athens, GA, United States
Lee, Kyeong, Athens, GA, United States
Hong, Joon H., Athens, GA, United States
PA Emory University, Atlanta, GA, United States (U.S. corporation)
University of Georgia Research Foundation, Inc., Athens, GA, United States (U.S. corporation)
PI US 6348587 B1 20020219
AI US 1999-257130 19990225 (9)
PRAI US 1998-80569P 19980403 (60)
US 1998-75893P 19980225 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Riley, Jezia
LREP Knowles, Esq., Sherry M., Young, Josephine, King & Spalding
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A class of 2'-fluoro-nucleoside compounds are disclosed which are useful in the treatment of **hepatitis B** infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: ##STR1##

wherein

Base is a purine or pyrimidine base; R.sup.1 is OH, H, OR.sup.3, N.sub.3, CN, halogen, including F, or CF.sub.3, lower alkyl, amino,

09567863

loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base;

R.sup.2 is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R.sup.2 is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and

R.sup.3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:42:34 ON 07 MAR 2003)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:42:52 ON 07 MAR 2003
L1 2 S HEPATITIS B AND 2 (W) FLUORO BETA D NUCLEOSIDE

=> s (hepatitis or HIV or cell proliferation) and 2 (w) fluoro (2a) nucleoside
4 FILES SEARCHED...
L2 51 (HEPATITIS OR HIV OR CELL PROLIFERATION) AND 2 (W) FLUORO (2A) NUCLEOSIDE

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3 39 DUP REM L2 (12 DUPLICATES REMOVED)

=> s l3 and (beta L or beta D)
L4 28 L3 AND (BETA L OR BETA D)

=> d l4 bib abs 1-28

L4 ANSWER 1 OF 28 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1998:253474 BIOSIS
DN PREV199800253474
TI Unique metabolism of a novel antiviral L-**nucleoside** analog, **2'-fluoro**-5-methyl-**beta-L**-arabinofuranosyluracil: A substrate for both thymidine kinase and deoxycytidine kinase.
AU Liu, Shwu-Huey; Grove, Kristie L.; Cheng, Yung-Chi (1)
CS (1) Dep. Pharmacol., Yale Univ. Sch. Med., Sterling Hall Med., 333 Cedar St., New Haven, CT 06510 USA
SO Antimicrobial Agents and Chemotherapy, (April, 1998) Vol. 42, No. 4, pp. 833-839.
ISSN: 0066-4804.
DT Article
LA English
AB 2'-Fluoro-5-methyl-**beta-L**-arabinofuranosyluracil (L-FMAU) is the first L-nucleoside analog with low cytotoxicity discovered to have potent antiviral activities against both **hepatitis** B virus and Epstein-Barr virus but not human immunodeficiency virus. This

spectrum of activity is different from those of the other L-nucleoside analogs examined. L-FMAU enters cells through equilibrative-sensitive and -insensitive nucleoside transport as well as through nonfacilitated passive diffusion. L-FMAU is phosphorylated stepwise in cells to its mono-, di-, and triphosphate forms. In the present study the enzymes responsible for the first step of L-FMAU phosphorylation were identified. This is the first thymidine analog shown to he a substrate not only for cytosolic thymidine kinase and mitochondrial deoxypyrimidine kinase pot also for deoxycytidine kinase. This finding suggests that the antiviral activity of L-FMAU will not be limited by the loss or alteration of any of these deoxynucleoside kinases.

L4 ANSWER 2 OF 28 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1996:151744 BIOSIS
DN PREV199698723879
TI Inhibition of **hepatitis** B virus by a novel L-**nucleoside**, **2'-fluoro**-5-methyl-**beta-L**-arabinofuranosyl uracil.
AU Pai, S. Balakrishna; Liu, Shwu-Huey; Zhu, Yong-Lian; Chu, Chung K.; Cheng, Yung-Chi (1)
CS (1) Dep. Pharmacol., Yale Sch. Med., Yale Univ., 333 Cedar St., New Haven, CT 06510 USA
SO Antimicrobial Agents and Chemotherapy, (1996) Vol. 40, No. 2, pp. 380-386. ISSN: 0066-4804.
DT Article
LA English
AB 2'-Fluoro-5-methyl-**beta-L**-arabinofuranosyl uracil (L-FMAU) was discovered to have potent antiviral activity against **hepatitis** B virus (HBV). L-FMAU was more potent than its D-enantiomer and produced dose-dependent inhibition of the viral DNA replication in 2.2.15 cells (human HepG2 cells with the HBV genome), with a 50% inhibitory concentration of 0.1 mu-M. There was no inhibitory effect on HBV transcription or protein synthesis. In the 2.2.15 cell system, L-FMAU did not show any toxicity up to 200 mu-M, whereas the D-enantiomer was toxic, with a 50% inhibitory concentration of 50 mu-M. Repeated treatments of HepG2 cells with L-FMAU at a 1 mu-M concentration for 9 days did not result in any decrease in the total mitochondrial DNA content, suggesting that a mode of toxicity similar to that produced by 2',3'-dideoxycytidine is unlikely. Also at concentrations as high as 200 mu-M, L-FMAU did not adversely affect mitochondrial function as determined by lactic acid production by L-FMAU-treated hepatoma cells. L-FMAU was metabolized in the cells to its mono-, di-, and triphosphates. A dose-dependent inhibition of HBV DNA synthesis by L-FMAU triphosphate was observed in the DNA polymerase assays with isolated HBV particles, suggesting that the mode of action of this compound could involve viral polymerase. However, L-FMAU was not incorporated into the cellular DNA. Considering the potent inhibition of the viral DNA synthesis and the nontoxicity of L-FMAU towards the host DNA synthetic machinery, this compound should be further explored for development as an anti-HBV drug.

L4 ANSWER 3 OF 28 MEDLINE
AN 2000190260 MEDLINE
DN 20190260 PubMed ID: 10726061
TI Preclinical investigation of L-FMAU as an anti-**hepatitis** B virus agent.
AU Chu C K; Boudinot F D; Peek S F; Hong J H; Choi Y; Korba B E; Gerin J L; Cote P J; Tennant B C; Cheng Y C
CS University of Georgia College of Pharmacy, Athens 30602, USA..
DChu@RX.UGA.EDU
NC AI 25899 (NIAID)
AI 32351 (NIAID)
N01-AI-45195 (NIAID)

09567863

+
SO ANTIVIRAL THERAPY, (1998) 3 (Suppl 3) 113-21. Ref: 43
Journal code: 9815705. ISSN: 1359-6535.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200004
ED Entered STN: 20000505
Last Updated on STN: 20000505
Entered Medline: 20000426
AB Preclinical aspects of a potent anti-**hepatitis** B virus (HBV) L-**nucleoside**, 1-(**2**-**fluoro**-5-methyl-**beta**-**L**-arabino-furanosyl)uracil (L-FMAU) are described. L-FMAU was prepared from L-ribose derivatives via either L-xylose or L-arabinose. L-FMAU shows potent antiviral activity against **hepatitis** B virus (EC50 5.0 microM in H1 cells) with high selectivity in vitro. L-FMAU is not incorporated into mitochondrial DNA and no significant lactic acid production was observed in vitro. L-FMAU is phosphorylated by thymidine kinase as well as deoxycytidine kinase, ultimately to the triphosphate, which inhibits HBV DNA polymerase as the mechanism of antiviral action. Preliminary in vivo toxological studies suggest no apparent toxicity for 30 days at 50 mg/kg/day in mice and for 3 months in woodchucks (10 mg/kg/day). L-FMAU also has respectable bioavailability in rats. L-FMAU shows potent anti-HBV activity in vivo against woodchuck **hepatitis** virus in chronically infected woodchucks and there is no significant virus rebound after cessation of the drug treatment.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2003 ACS
AN 2001:914990 CAPLUS
DN 136:34011
TI 2'-deoxy-2'-fluoro-D-arabinofuranosyl pyrimidine nucleoside
IN Conti, Peter S.; Alauddin, Mian M.; Fissekis, John D.
PA University Advanced Bio-Imaging Associates, USA
SO U.S., 13 pp., Cont.-in-part of U.S. 5,879,661.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6331287	B1	20011218	US 1998-36352	19980306
	US 5879661	A	19990309	US 1995-518407	19950823
	WO 9944646	A1	19990910	WO 1999-US4935	19990305
	W: CA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1995-518407	A2	19950823		
	US 1998-36352	A	19980306		

AB The **nucleoside** analog **2'**-**fluoro**-5-methyl-1-.**beta**.-**D**-arabinofuranosyluracil (FMAU) has been found to have an esp. desirable combination of properties for use as an imaging agent, including in particular limited in vivo catabolism. An example of brain tumor PET imaging with the 11C-labeled analog is given. Methods for the prepn. of the [11C]- and [18F]-labeled FMAU are also provided.
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2003 ACS
AN 1999:576818 CAPLUS

09567863

DN 131:196459
TI Novel nucleoside imaging agents and methods for the preparation and use thereof
IN Conti, Peter S.; Alauddin, Mian M.; Fissekis, John D.
PA University Advanced Bio-Imaging Associates, USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9944646	A1	19990910	WO 1999-US4935	19990305
	W: CA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6331287	B1	20011218	US 1998-36352	19980306
PRAI	US 1998-36352	A	19980306		
	US 1995-518407	A2	19950823		

AB The **nucleoside** analog **2'-fluoro**-5-methyl-1-.**beta.-D**-arabinofuranosyluracil (FMAU) has been found to have an esp. desirable combination of properties for use as an imaging agent, in particular limited in vivo catabolism. Methods for the prepn. of [11C]- and [18F]-labeled FMAU and for the use of the labeled material are provided. It was found that [11C]FMAU is a superior in vivo imaging agent for detecting **cell proliferation**, and appropriate dose is about 20-25 mCi.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2003 ACS
AN 1999:566061 CAPLUS
DN 131:170587
TI Preparation of 2'-fluoro nucleosides as antiviral agents
IN Schinazi, Raymond F.; Liotta, Dennis C.; Chu, Chung K.; Mcatee, J. Jeffrey; Shi, Junxing; Choi, Yongseok; Lee, Kyeong; Hong, Joon H.
PA Emory University, USA; The University of Georgia Research Foundation, Inc.
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9943691	A1	19990902	WO 1999-US4051	19990225
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2322008	AA	19990902	CA 1999-2322008	19990225
	AU 9927871	A1	19990915	AU 1999-27871	19990225
	EP 1058686	A1	20001213	EP 1999-908437	19990225
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
	JP 2002504558	T2	20020212	JP 2000-533443	19990225
	US 6348587	B1	20020219	US 1999-257130	19990225
	US 2002198171	A1	20021226	US 2002-61128	20020130
PRAI	US 1998-75893P	P	19980225		

09567863

US 1998-80569P P 19980403
US 1999-257130 A1 19990225
WO 1999-US4051 W 19990225
OS MARPAT 131:170587
GI



AB **2'-Fluoro nucleoside** compds. I wherein R1 is OH, H, OR3, N3, CN, halogen, including F, or CF3, lower alkyl, amino, lower alkylamino, or alkoxy, and base refers to a purine or pyrimidine base; R2 is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo , is capable of providing a compd. wherein R2 is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the Ph group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo , is capable of being cleaved to the parent compd., or a pharmaceutically acceptable salt thereof, are disclosed which are useful in the treatment of **hepatitis** B infection, **hepatitis** C infection, **HIV** and abnormal cellular proliferation, including tumors and cancer. Thus, 1-(2,3-dideoxy-2-fluoro-.**beta**.-**L**-glycero-pent-2-eno-furanosyl)thymine was prepd. and tested for its antiviral activity (EC50 > 100 .mu.M).
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 28 WPIDS (C) 2003 THOMSON DERWENT
AN 1988-280187 [40] WPIDS
DNC C1988-124730
TI New and known antiviral **2' fluoro nucleoside** (s) - e.g. 2,6-di amino-9- (2-deoxy-2-fluoro- **beta-D** -arabinofuranosyl) -9H-purine, to treat **HIV** infections and aids.
DC B02
IN KRENITSKY, T A; TUTTLE, J V; VAN, TUTTLE J
PA (WELL) WELLCOME FOUND LTD; (WELL) BURROUGHS WELLCOME CO
CYC 19
PI EP 285432 A 19881005 (198840)* EN 16p
R: AT BE CH DE ES FR GB GR IT LI LU NL SE
AU 8814120 A 19881006 (198848)
JP 63258891 A 19881026 (198849)
DK 8801778 A 19881004 (198851)
HU 48268 T 19890529 (198926)
ZA 8802344 A 19891227 (199005)
EP 285432 B1 19921111 (199246) EN 21p
R: AT BE CH DE ES FR GB GR IT LI LU NL SE
DE 3875769 G 19921217 (199252)
US 5175274 A 19921229 (199303) 8p
ADT EP 285432 A EP 1988-302922 19880331; JP 63258891 A JP 1988-80186 19880331; ZA 8802344 A ZA 1988-2344 19880331; EP 285432 B1 EP 1988-302922 19880331;

09567863

DE 3875769 G DE 1988-3875769 19880331, EP 1988-302922 19880331; US 5175274 A Cont of US 1988-175958 19880331, US 1991-771619 19911004
FDT DE 3875769 G Based on EP 285432
PRAI GB 1987-8050 19870403
AN 1988-280187 [40] WPIDS
AB EP 285432 A UPAB: 19930923
Use of 2'-fluoronucleosides of formula (I) and their pharmaceutically acceptable derivs. in medical therapy is new. R = H, OH, 1-6C alkyl, 1-6C alkoxy or amino (opt. substd by 1-6C alkyl, 1-6C alkoxy or 3-6C cycloalkyl. Cpds. (I) excluding those where R = OH, NH2 or H are new.
USE - (I) are useful for the treatment of prophylaxis of viral infections esp. human retroviral infections, e.g. Human immunodeficiency virus (**HIV**), **HIV**-2, Human T-cell lymphotropic virus (HLTV), e.g. HTLV-1 or HTLV-IV infections and esp. AIDS or AIDS related conditions such as AIDS-related complex (ARC), progressive generalised lymphadenopathy (PGL), AIDS-related neurological conditions such as multiple sclerosis or tropical paraparesis, anti-**HIV** antibody-positive and **HIV** positive conditions, kaposis sarcoma and thrombocytopenic purpura. (I) may also be useful for the treatment or prophylaxis of psoriasis.
0/0
ABEQ EP 285432 B UPAB: 19930923
A compound of general formula (I)B in which R represents either C1-6 alkyl, or amino substituted by C1-6 alkoxy or C3-6 cycloalkyl or a pharmaceutically acceptable derivative thereof.
0/0
ABEQ US 5175274 A UPAB: 19930923
2-Amino-6-(cyclopropylamino) -9-(2-dioxy-2-fluoro-**beta**-**D** -arabino furanosyl)-9H-purine is new.
Prepn. is e.g. by treating 1-2-deoxy-2-fluoro-**beta**-**D**-2-amino -6-(cyclopropylamino)-purine hydrochloride and 2-(3-deoxy-2-fluoro-**beta**-**D** -arabinofuranosyl)-thymine in KN3phosphate buffer with thymidine phosphorylase and purine nucleoside phosphorylase.
USE - Used as antiviral agent for treatment of **HIV** infection and dosage 3-120 (15-60) mg/kg/day.
0/0

L4 ANSWER 8 OF 28 USPATFULL
AN 2003:60295 USPATFULL
TI Synthetic ribonucleic acids with RNAse activity
IN Beigelman, Leonid, Broomfield, CO, United States
Burgin, Alex, Chula Vista, CA, United States
Beaudry, Amber, Broomfield, CO, United States
Karpeisky, Alexander, Lafayette, CO, United States
Matulic-Adamic, Jasenka, Boulder, CO, United States
Sweedler, David, Louisville, CO, United States
Zinnen, Shawn, Denver, CO, United States
PA Ribozyme Pharmaceuticals, incorporated, Boulder, CO, United States (U.S. corporation)
PI US 6528640 B1 20030304
AI US 1999-474432 19991229 (9)
RLI Continuation-in-part of Ser. No. US 1999-301511, filed on 28 Apr 1999
Continuation-in-part of Ser. No. US 1998-186675, filed on 4 Nov 1998, now patented, Pat. No. US 6127535
PRAI US 1998-83727P 19980429 (60)
US 1997-64866P 19971105 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Crane, L. E.
LREP McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 3

09567863

ECL Exemplary Claim: 1,2
DRWN 23 Drawing Figure(s); 21 Drawing Page(s)
LN.CNT 3964
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel nucleotide triphosphates, methods of synthesis and process of incorporating these nucleotide triphosphates into oligonucleotides, and isolation of novel nucleic acid catalysts (e.g., ribozymes) are disclosed. Also, described are the use of novel enzymatic nucleic acid molecules to inhibit HER2/neu/ErbB2 gene expression and their applications in human therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 28 USPATFULL
AN 2003:4083 USPATFULL
TI Nucleotide triphosphates and their incorporation into oligonucleotides
IN Beigelman, Leonid, Longmont, CO, UNITED STATES
Burgin, Alex, San Diego, CA, UNITED STATES
Beaudry, Amber, Denver, CO, UNITED STATES
Karpeisky, Alexander, Lafayette, CO, UNITED STATES
Matulic-Adamic, Jasenka, Boulder, CO, UNITED STATES
Sweedler, David, Louisville, CO, UNITED STATES
Zinnen, Shawn, Denver, CO, UNITED STATES
PI US 2003004122 A1 20030102
AI US 2001-825805 A1 20010404 (9)
RLI Continuation-in-part of Ser. No. US 2000-578223, filed on 23 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-476387, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-474432, filed on 29 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-301511, filed on 28 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-186675, filed on 4 Nov 1998, GRANTED, Pat. No. US 6127535
PRAI US 1998-83727P 19980429 (60)
US 1997-64866P 19971105 (60)
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN 33 Drawing Page(s)
LN.CNT 5252
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel nucleotide triphosphates, methods of synthesis and process of incorporating these nucleotide triphosphates into oligonucleotides, and isolation of novel nucleic acid catalysts (e.g., ribozymes or DNAzymes). Also, provided are the use of novel enzymatic nucleic acid molecules to inhibit HER2/neu/ErbB2 gene expression and their applications in human therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 28 USPATFULL
AN 2002:344441 USPATFULL
TI 2'-fluoronucleosides
IN Schinazi, Raymond F., Decatur, GA, UNITED STATES
Liotta, Dennis C., McDonough, GA, UNITED STATES
Chu, Chung K., Athens, GA, UNITED STATES
McAtee, J. Jeffrey, Mobile, AL, UNITED STATES
Shi, Junxing, Decatur, GA, UNITED STATES
Choi, Yongseok, Athens, GA, UNITED STATES
Lee, Kyeong, Athens, GA, UNITED STATES
Hong, Joon H., Athens, GA, UNITED STATES

09567863

PI US 2002198171 A1 20021226
AI US 2002-61128 A1 20020130 (10)
RLI Continuation of Ser. No. US 1999-257130, filed on 25 Feb 1999, GRANTED, Pat. No. US 6348587
PRAI US 1998-75893P 19980225 (60)
US 1998-80569P 19980403 (60)
DT Utility
FS APPLICATION
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3626
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A class of **2'-fluoro-nucleoside** compounds are disclosed which are useful in the treatment of **hepatitis** B infection, **hepatitis** C infection, **HIV** and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: ##STR1##

wherein

Base is a purine or pyrimidine base;

R.sup.1 is OH, H, OR.sup.3, N.sub.3, CN, halogen, including F, or CF.sub.3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base;

R.sup.2 is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R.sup.2 is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and

R.sup.3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 28 USPATFULL
AN 2002:295153 USPATFULL
TI Nucleosides for imaging and treatment applications
IN Klecker, Raymond W., Silver Spring, MD, UNITED STATES
Anderson, Lawrence, Wheaton, MD, UNITED STATES
Katki, Aspandiar G., Gaithersburg, MD, UNITED STATES
Collins, Jerry M., Rockville, MD, UNITED STATES
PA The Gov. of the USA respresented by the Secretary of Health and Human Services (U.S. corporation)
PI US 2002165199 A1 20021107
AI US 2002-122173 A1 20020416 (10)
RLI Continuation of Ser. No. US 2001-941552, filed on 30 Aug 2001, PENDING Division of Ser. No. US 2000-530276, filed on 28 Apr 2000, PENDING A 371 of International Ser. No. WO 1998-US23109, filed on 30 Oct 1998, UNKNOWN
PRAI US 1997-63587P 19971030 (60)
DT Utility
FS APPLICATION

09567863

LREP VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1397
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 28 USPATFULL
AN 2002:288110 USPATFULL
TI Method of treating **hepatitis** delta virus infection
IN Casey, John L., Potomac, MD, UNITED STATES
Korba, Brent E., Laurel, MD, UNITED STATES
Cote, Paul J., New Market, MD, UNITED STATES
Gerin, John L., Bethesda, MD, UNITED STATES
Tennant, Bud C., Ithaca, NY, UNITED STATES
Chu, Chung K., Athens, GA, UNITED STATES
PI US 2002160980 A1 20021031
AI US 2001-821278 A1 20010329 (9)
PRAI US 2000-193135P 20000329 (60)
DT Utility
FS APPLICATION
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1880
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the treatment for **hepatitis** delta infection in a host, that includes administering an effective amount of a nucleoside or a nucleoside analog that suppresses the expression of the **hepatitis** B surface or preS1 antigen in the host 100-fold or more relative to pretreatment values in vivo; or to not more than 1 microgram per milliliter in vivo. In a preferred embodiment, the nucleoside is L-FMAU, or a pharmaceutically acceptable salt or prodrug thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 28 USPATFULL
AN 2002:220960 USPATFULL
TI Nucleosides for imaging and treatment applications
IN Klecker, Raymond W., Silver Spring, MD, UNITED STATES
Anderson, Lawrence, Wheaton, MD, UNITED STATES
Katki, Aspandiar G., Gaithersburg, MD, UNITED STATES
Collins, Jerry M., Rockville, MD, UNITED STATES
PA The Government of the United States of America, Secretary of Health and Human Services (U.S. corporation)
PI US 2002119094 A1 20020829
AI US 2001-941552 A1 20010830 (9)
RLI Division of Ser. No. US 2000-530276, filed on 28 Apr 2000, PENDING A 371 of International Ser. No. WO 1998-US23109, filed on 30 Oct 1998, UNKNOWN
PRAI US 1997-63587P 19971030 (60)

09567863

DT Utility
FS APPLICATION
LREP VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1397
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 28 USPATFULL
AN 2002:106274 USPATFULL
TI 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections
IN Watanabe, Kyoichi A., Stone Mountain, GA, UNITED STATES
Pai, S. Balakrishna, Chamblee, GA, UNITED STATES
PI US 2002055483 A1 20020509
AI US 2001-834596 A1 20010413 (9)
PRAI US 2000-197068P 20000413 (60)
US 2000-202663P 20000508 (60)
DT Utility
FS APPLICATION
LREP TROUTMAN SANDERS LLP, BANK OF AMERICA PLAZA, SUITE 5200, 600 PEACHTREE STREET , NE, ATLANTA, GA, 30308-2216
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4961
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a composition for and a method of treating hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection or a proliferative disorder in a patient using an effective amount of a compound selected from the group consisting of formulas [I]- [IV] below and mixtures of two or more thereof: ##STR1##

wherein the substituents are as defined herein. Pharmaceutical compositions comprising these compounds in combination with other HBV, HCV, or HDV agents is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 28 USPATFULL
AN 2002:60639 USPATFULL
TI Nucleosides for imaging and treatment applications
IN Klecker, Raymond W., Silver Spring, MD, UNITED STATES
Anderson, Lawrence, Wheaton, MD, UNITED STATES
Katki, Aspandiar G., Gaithersburg, MD, UNITED STATES
Collins, Jerry M., Rockville, MD, UNITED STATES
PI US 2002034473 A1 20020321
AI US 2001-941571 A1 20010830 (9)
RLI Division of Ser. No. US 2000-530276, filed on 28 Apr 2000, PENDING A 371 of International Ser. No. WO 1998-US23109, filed on 27 Oct 1998, UNKNOWN

09567863

PRAI US 1997-63587P 19971030 (60)
DT Utility
FS APPLICATION
LREP VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1397
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 28 USPATFULL
AN 2002:37285 USPATFULL
TI Nucleosides for imaging and treatment applications
IN Klecker, Raymond W., Silver Spring, MD, UNITED STATES
Anderson, Lawrence, Wheaton, MD, UNITED STATES
Katki, Aspandiar G., Gaithersburg, MD, UNITED STATES
Collins, Jerry M., Rockville, MD, UNITED STATES
PA The Government of the United States of America, Secretary of Health and Human Services (U.S. corporation)
PI US 2002022001 A1 20020221
AI US 2001-941550 A1 20010830 (9)
RLI Division of Ser. No. US 2000-530276, filed on 28 Apr 2000, PENDING A 371 of International Ser. No. WO 1998-US23109, filed on 30 Oct 1998, UNKNOWN
PRAI US 1997-63587P 19971030 (60)
DT Utility
FS APPLICATION
LREP VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 28 USPATFULL
AN 2001:114640 USPATFULL
TI Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
IN Lori, Franco, Parma, Italy
Cara, Andrea, Rockville, MD, United States
Gao, Wen-Yi, Rockville, MD, United States
Gallo, Robert C., Bethesda, MD, United States
PI US 2001008905 A1 20010719

09567863

AI US 2001-756411 A1 20010108 (9)
RLI Continuation of Ser. No. US 2000-497770, filed on 4 Feb 2000, PENDING Continuation of Ser. No. US 1994-245259, filed on 17 May 1994, GRANTED, Pat. No. US 6046175 Continuation-in-part of Ser. No. US 1993-65815, filed on 21 May 1993, GRANTED, Pat. No. US 5462103
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse-transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 28 USPATFULL
AN 2001:93644 USPATFULL
TI Nucleoside analogs
IN Matulic-Adamic, Jasenka, Boulder, CO, United States
Beigelman, Leonid, Longmont, CO, United States
Karpeisky, Alexander, Lafayette, CO, United States
PA Ribozyme Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)
PI US 6248878 B1 20010619
AI US 1997-975238 19971121 (8)
PRAI US 1996-34444P 19961224 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wilson, James O.
LREP McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 1498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel nucleoside analogs, such as 3-(.**beta**.-**D**-Ribofuranosyl)-2-fluoropyridine, 3-(.**beta**.-**D**-Ribofuranosyl)-pyridin-2-one, 3-(.**beta**.-**D**-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one, 3-(.alpha.-D-Ribofuranosyl)-2-fluoropyridine, 5-(.**beta**.-**D**-Ribofuranosyl)-2-bromopyridine, 5-(.alpha.-D-Ribofuranosyl)-2-bromopyridine, 5-(.**beta**.-**D**-Ribofuranosyl)-pyridin-2-one, 5-(.alpha.-D-Ribofuranosyl)-pyridin-2-one, 5-(.**beta**.-**D**-Ribofuranosyl)-2-aminopyridine, 5-(.**beta**.-**D**-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one, and 5-(.alpha.-D-Ribofuranosyl)-2-aminopyridine; process for their synthesis and incorporation into polynucleotides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 28 USPATFULL

09567863

AN 2001:44373 USPATFULL
TI High affinity oligonucleotide ligands to growth factors
IN Gold, Larry, Boulder, CO, United States
Janjic, Neboisa, Boulder, CO, United States
Pagratis, Nikos, Boulder, CO, United States
PA NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)
PI US 6207816 B1 20010327
WO 9638579 19961205
AI US 1998-973124 19980511 (8)
WO 1996-US8014 19960530
19980511 PCT 371 date
19980511 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-465594, filed on 5 Jun 1995, now patented, Pat. No. US 5846713 Continuation-in-part of Ser. No. US 1995-465591, filed on 5 Jun 1995, now patented, Pat. No. US 5837834 Continuation-in-part of Ser. No. US 1995-479725, filed on 7 Jun 1995, now patented, Pat. No. US 5674685 Continuation-in-part of Ser. No. US 1995-479783, filed on 7 Jun 1995, now patented, Pat. No. US 5668264 Continuation-in-part of Ser. No. US 1996-618693, filed on 20 Mar 1996, now patented, Pat. No. US 5723594 Continuation-in-part of Ser. No. US 1995-458423, filed on 2 Jun 1995, now patented, Pat. No. US 5731144 Continuation-in-part of Ser. No. US 1995-458424, filed on 2 Jun 1995, now patented, Pat. No. US 5731424
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie
LREP Swanson & Bratschun LLC
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 3643
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:42:34 ON 07 MAR 2003)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:42:52 ON 07 MAR 2003
L1 2 S HEPATITIS B AND 2 (W) FLUORO BETA D NUCLEOSIDE
L2 51 S (HEPATITIS OR HIV OR CELL PROLIFERATION) AND 2 (W) FLUORO (2A
L3 39 DUP REM L2 (12 DUPLICATES REMOVED)
L4 28 S L3 AND (BETA L OR BETA D)

=> s l4 and 2 (W) FLUORO (beta l or beta d) nucleo?
MISSING OPERATOR 'FLUORO (BETA'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l4 and 2(w) fluoro (2a) (beta L or Beta D) nucleo?
MISSING OPERATOR D) NUCLEO?
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l4 and 2(w) fluoro (2a) (beta L or Beta D) (w) nucleo?
L5 2 L4 AND 2(W) FLUORO (2A) (BETA L OR BETA D) (W) NUCLEO?

=>

09567863

=> d his

(FILE 'HOME' ENTERED AT 15:42:34 ON 07 MAR 2003)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:42:52 ON 07 MAR 2003

L1 2 S HEPATITIS B AND 2 (W) FLUORO BETA D NUCLEOSIDE
L2 51 S (HEPATITIS OR HIV OR CELL PROLIFERATION) AND 2 (W) FLUORO (2A
L3 39 DUP REM L2 (12 DUPLICATES REMOVED)
L4 28 S L3 AND (BETA L OR BETA D)
L5 2 S L4 AND 2(W) FLUORO (2A) (BETA L OR BETA D) (W) NUCLEO?

=> s l5 not l1
L6 1 L5 NOT L1

=> d l6 bib abs

L6 ANSWER 1 OF 1 USPATFULL
AN 2002:106274 USPATFULL
TI 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections
IN Watanabe, Kyoichi A., Stone Mountain, GA, UNITED STATES
Pai, S. Balakrishna, Chamblee, GA, UNITED STATES
PI US 2002055483 A1 20020509
AI US 2001-834596 A1 20010413 (9)
PRAI US 2000-197068P 20000413 (60)
US 2000-202663P 20000508 (60)
DT Utility
FS APPLICATION
LREP TROUTMAN SANDERS LLP, BANK OF AMERICA PLAZA, SUITE 5200, 600 PEACHTREE STREET , NE, ATLANTA, GA, 30308-2216
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4961
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a composition for and a method of treating hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection or a proliferative disorder in a patient using an effective amount of a compound selected from the group consisting of formulas [I]- [IV] below and mixtures of two or more thereof: ##STR1##

wherein the substituents are as defined herein. Pharmaceutical compositions comprising these compounds in combination with other HBV, HCV, or HDV agents is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>